Peter Fenici

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

Mikhail Kosiborod, Matthew A. Cavender, Alex Z. Fu et al. · Circulation · 2017 · 814 citations · Full text

Medicine, Cardiology, Pharmacology +16

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 371 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Hiddo J.L. Heerspink, Avraham Karasik, Marcus Thuresson et al. · The Lancet Diabetes & Endocrinology · 2019 · 303 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +12

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)

Mikhail Kosiborod, Marília Brito Gomes, Antonio Nicolucci et al. · Cardiovascular Diabetology · 2018 · 263 citations · Full text

Medicine, Internal Medicine, Clinical Epidemiology +12

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( <scp>CVD‐REAL Nordic</scp> ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: <scp>A</scp> multinational observational study

Frederik Persson, Thomas Nyström, Marit E. Jørgensen et al. · Diabetes Obesity and Metabolism · 2017 · 217 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17